查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球造影剂注射器市场
市场调查报告书
商品编码
1146446

2022-2029 年全球造影剂注射器市场

Global Contrast Media Injectors Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 250 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

造影剂注射器的全球市场规模预计将在 2021 年达到 XX 万美元，在 2029 年达到 XX 万美元，在预测期间（2022-2029 年）以 6.8% 的复合年增长率增长。

造影剂注射器是一种医疗设备，用于将造影剂注入人体，以在医学成像期间增强组织的可见性。技术进步将促进造影剂使用的自动控制、自动数据收集和每位患者的个性化剂量。

市场动态

造影剂注射器市场的增长受到创伤增加、成像中心数量增加、老年人口增加以及研发活动的推动。

心血管疾病患病率上升预计将推动市场增长

在预测期内，技术进步和放疗使用的增加预计将推动市场扩张 据世界卫生组织 (WHO) 称，心血管疾病是全球第一大死因。每年约有 1790 万人患有心血管疾病。超过五分之四的心血管疾病死亡是由于心脏病发作和中风，其中三分之一的死亡发生在 70 岁之前。越来越多的需要诊断的心血管疾病患者导致对造影剂注射器的需求增加。

此外，市场参与者正在采取产品发布和合作等市场策略。例如，2021 年 12 月，Qaelum NV 将与乌尔姆的 Ulrich GmbH & Co.KG 合作，将公司先进的造影剂管理解决方案与 Ulrich Medical 的造影剂注射器相结合，以满足医院和成像网络的需求，并宣布支持。同样在 2020 年 5 月，德国医疗技术公司 Ulrich Medical 在芝加哥的 RSNA 推出了一款专为美国市场设计的 CT 运动造影剂注射器。 FDA 与 GE Healthcare 合作批准和销售。

造影剂的副作用阻碍市场增长

但是，X 射线造影剂的副作用从轻微的不便（如瘙痒）到危及生命的紧急情况。造影剂引起的肾病是与使用静脉内或动脉内造影剂相关的副作用。此外，还有迟发性过敏反应、过敏反应、皮肤反应等副反应。

COVID-19 影响分析

COVID-19 的出现对全球造影剂注射器市场产生了相当大的影响。 2020年4月发表在放射学杂誌上的一篇文章发现，在大流行期间，由于经济失衡，医疗保健支出下降。放射学公司从未经历过因需要限制获得诊断成像而加剧的经济衝击。拥有大量门诊患者的诊所感受到了这些变化的最大影响，但所有图像处理量都减少了。放射科诊所应该预计成像吞吐量会减少 50%-70%，持续至少 3-4 个月，具体取决于诊所位置和每个地区 COVID-19 大流行的严重程度。在大流行期间，许多患者将难以获得医疗保健，这将对市场产生负面影响。

同时，到 2022 年，情况已经从 COVID-19 中恢復过来，几乎所有患者都可以使用先进的医疗设施。完善的诊断中心和服务患者正在推动全球市场的发展。

细分分析

预计 CT 细分市场在预测期间（2022-2029 年）将以最快的复合年增长率增长。

预计 CT 细分市场将在预测期内提振市场。根据 2022 年 4 月发表在《医疗器械证据与研究》上的一篇文章，全球对比增强 CT（计算机断层扫描）检查的数量正在逐年增加。扫描仪技术的进步和多排 CT (MDCT) 的可用性使执行扫描的时间更加简洁。在此背景下，开发了一种新的 CT 注射装置，在保持活塞式註射装置（如 Stellant CT 注射装置）的液体传输性能的同时提高了时间效率。现在您可以更专注于您的患者，而无需花费太多很多时间处理它们。新的计量系统在技术流体输送性能方面与当前的活塞系统非常相似，但主要区别在于工作流程的特点。

此外，市场参与者正在应用收购和产品发布等市场策略。例如，2021 年 12 月，Qaelum NV 与乌尔姆的 Ulrich GmbH & Co. KG 达成协议，将其造影剂管理技术与 Ulrich 医用造影剂注射器相结合，以满足医院和成像网络的需求。

区域分析

北美在全球造影剂市场占有最大份额

北美在造影剂注射器市场中占主导地位，预计在预测期内将呈现类似趋势。由于先进的医疗基础设施、老龄化社会的进步、技术进步、产品批准等，估计在预测期间（2022-2029 年）将占据相当大的市场规模。

大量主要参与者的存在以及产品和服务的现成可用性推动了市场。例如，Ulrich Medical 提供用于计算机断层扫描 (CT) 和磁共振成像 (MRI) 的造影剂注射器。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 技术进步
      • 激活研发
    • 限制因素
      • 造影剂注射器价格飙升
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 法律法规分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按正面数

  • 单头
  • 双头
  • 三头

第 8 章按设备

  • CT
  • 血管造影
  • 核磁共振
  • 其他

第 9 章。可移植性

  • 固定式
  • 可移动

第 10 章按应用程序

  • 介入心脏病学
  • 肿瘤学
  • 神经内科
  • 介入放射学
  • 其他

第 11 章，最终用户

  • 诊断中心
  • 医院
  • 其他

第 12 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 13 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按治疗类型划分的基准

第 14 章公司简介

  • Bracco Imaging
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Guerbet Group
  • Imaxeon
  • Medtronic
  • Nemoto
  • M. Schilling GmbH Medical Products
  • PTM-Network Services GmbH
  • Shenzhen Anke High-Tech
  • Ulrich Medical
  • Vivid Imaging

第15章 全球造影剂市场-DataM

简介目录
Product Code: DMMD108

Market Overview

The global contrast media injectors market size was growing at a CAGR of 6.8% during the forecast period (2022-2029).

Contrast media injectors are medical devices utilized for injecting contrast media into the human body to increase the visibility of tissues for medical imaging procedures. Due to technological advancements, automated systems control the amount of contrast media agents used and promote automated data collection and personalized doses for each patient.

Market Dynamics

The contrast media injectors market growth is driven by the rise in trauma cases, rising diagnostic imaging centers, increasing the geriatric population, and research and development activities.

The rising prevalence of cardiovascular diseases is expected to drive the market growth

Technological advancement and rising radiological procedures are expected to boost the market over the forecast period. As per the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Each year around 17.9 million people suffer from cardiovascular disease. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths happen prematurely in people under 70. The increasing number of patients with cardiovascular disease that need to be diagnosed leads to increasing demand for contrast media injectors.

In addition, the market players are adopting market strategies, including product launches and collaboration. For instance, in December 2021, Qaelum NV partnered with Ulrich GmbH & Co. KG in Ulm to combine their advanced Contrast Management solution with the contrast media injectors of Ulrich Medical to support the needs of hospitals and imaging networks. Also, in May 2020, Ulrich Medical, a German medical technology company, presented a version of its CT motion contrast media injector designed for the American market at the RSNA in Chicago. It was authorized by the FDA and vended in cooperation with GE Healthcare.

The adverse effects of contrast media will hamper the growth of the market

However, side effects of radiographic contrast media range from mild inconveniences, such as itching, to a life-threatening emergency. Contrast-induced nephropathy is an adverse reaction associated with the use of intravenous or intra-arterial contrast material. In addition, adverse reactions such as delayed anaphylactic reactions, allergic reactions, and cutaneous reactions.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global contrast media injectors market. According to an article published in Radiology Journal in April 2020, during the pandemic, economic imbalances resulted in decreased healthcare expenditures. Radiology companies have never experienced an economic shock that is simultaneously worsened by the need to limit the availability of imaging. Outpatient-heavy practices felt the biggest impact of these changes, but all imaging volumes decreased. Radiology practices should anticipate a 50%-70% decrease in imaging volume that lasts a minimum of 3-4 months, as per the location of practice and the stringency of the COVID-19 pandemic in each region. During the pandemic, many patients faced access to healthcare treatment, leads to a negative impact on the market.

On the other hand, in 2022, the situation is recovering COVID- 19, and mostly every patient can access advanced healthcare facilities. Diagnostic centers are opening properly, and giving services to patients boosts the market worldwide.

Segment Analysis

The CT segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The CT segment is expected to boost the market over the forecast period. As per the article published in Medical Devices Evidence and Research in April 2022, The number of contrast-enhanced computed tomography (CT) examinations is rising worldwide each year. Because of the development of scanner technology and Multidetector CT (MDCT) availability, the time to conduct the scan has become more concise. A new CT injection system has been developed to maintain the fluid delivery benefits of a piston-based system (such as the Stellant CT injection system) but with the most elevated conceivable time efficiency, permitting the radiographer to spend less time handling the injector and disposables and more time concentrating on the patient. While the technical fluid delivery performance is very similar between this novel injection system and the current piston-based system, the major differences are in the workflow features.

In addition, the market players are applying the market strategies such as acquisition and product launches. For instance, in December 2021, to meet the demands of hospitals and imaging networks, Qaelum NV agreed with Ulrich GmbH & Co. KG in Ulm to merge their Contrast Management technology with Ulrich medical's contrast media injectors.

Geographical Analysis

North America region holds the largest market share of the global contrast media injectors market

North America dominates the market for contrast media injectors and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure, a rising aging population, technological advancement and approval of products.

As per the American Association for the Surgery of Trauma data, in 2020, trauma accounted for nearly 40 Mn homicide and suicide deaths each year in the US that occurred due to trauma. The rising number of patients with trauma leads to increasing demand for contrast media injectors in the North American region.

In addition, the presence of a large number of key players and easily availability of products and services drive the market. For instance, Ulrich medical offers contrast media injectors for usage in computed tomography (CT) and magnetic resonance imaging (MRI).

Competitive Landscape

The contrast media injectors market is a moderately competitive presence of local and global companies. Some key players contributing to the market's growth are Bracco Imaging, Guerbet Group, Imaxeon, Medtronic, Nemoto, M. Schilling GmbH Medical Products, PTM-Network Services GmbH, Shenzhen Anke High-Tech, Ulrich Medical, Vivid Imaging among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the global contrast media injectors market's growth.

For instance,

  • In December 2021, Guerbet and Bracco Imaging collaborated for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent.

Bracco Imaging

Overview:

Bracco Imaging is an Italian healthcare multinational company founded in 1927 and headquartered in Milan, Italy. The company developed specific contrast injectors for intravenous procedures in CT and MRI and for intraarterial procedures in Cardiac and or Peripheral intervention.

Product Portfolio:

CT Expres: It is a 3D Contrast Media Delivery System that is used for controlled automatic management, on the venous side of contrast media and saline, to human matters while experiencing examination by means of computed tomography (CT) scanner.

The global contrast media injectors market report would provide access to approximately 75+ market data tables, 75+ figures, and in the range of 250 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancement
      • 4.1.1.2. Increase research and development activities
    • 4.1.2. Restraints:
      • 4.1.2.1. Rising cost contrast media injectors
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Number of Heads

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 7.1.2. Market Attractiveness Index, By Number of Heads
  • 7.2. Single-Head*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Dual-Head
  • 7.4. Triple-Head

8. By Devices

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 8.1.2. Market Attractiveness Index, By Devices
  • 8.2. CT*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Angiography
  • 8.4. MRI
  • 8.5. Others

9. By Portability

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 9.1.2. Market Attractiveness Index, By Portability
  • 9.2. Fixed*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Movable

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Interventional Cardiology*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Oncology
  • 10.4. Neurology
  • 10.5. Interventional Radiology
  • 10.6. Others

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.1.2. Market Attractiveness Index, By End User
  • 11.2. Diagnostic Centres*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Hospitals
  • 11.4. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Number of Heads
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Devices
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Portability
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Treatment type Benchmarking

14. Company Profiles

  • 14.1. Bracco Imaging*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Guerbet Group
  • 14.3. Imaxeon
  • 14.4. Medtronic
  • 14.5. Nemoto
  • 14.6. M. Schilling GmbH Medical Products
  • 14.7. PTM-Network Services GmbH
  • 14.8. Shenzhen Anke High-Tech
  • 14.9. Ulrich Medical
  • 14.10. Vivid Imaging

LIST NOT EXHAUSTIVE

15. Global Contrast Media Injectors market- DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us